NEW YORK, Dec. 8 /PRNewswire-FirstCall/ -- Pfizer Inc announced today
that the Canadian Federal Court in Toronto has granted its application for
an order preventing Novopharm Ltd. from launching a generic version of
Lipitor until expiration of the product's patent (Canadian Patent
2,021,546) in July, 2010. The decision is subject to appeal.
"This is yet another decision recognizing the protection of the
intellectual property supporting Lipitor," said Pfizer General Counsel
Allen Waxman. "Patents like this one provide the incentive to develop new,
life- saving medicines that benefit millions of patients globally and
Pfizer will continue to vigorously defend its intellectual property rights
wherever they are challenged."
SOURCE Pfizer Inc
 back to top
Related links:
http://www.pfizer.com
Photo Notes:A free corporate logo to accompany this
story is availableimmediately via Wieck Photo Database to any
media with telephoto receiveror electronic darkroom, PC or
Macintosh, that can accept overheadtransmissions. To retrieve a
logo, please call 972-392-0888.
Pfizer's press releases are available through PR Newswire's
Company News On-Call service on PRN's Web Site. Visit
http://www.prnewswire.com/comp/688250.html/
CONTACT:
Bryant Haskins, +1-212-733-8719
|
